Join the club for FREE to access the whole archive and other member benefits.

Clinical trials now up for Exscientia's world first AI-made drug

Partnering with Japan's DSP, a milestone is reached in OCD treatment


Key points from article :

A candidate compound found within 350 synthesised compounds (typically just 2,500).

DSP-1181, created with DSP’s monoamine G protein-coupled receptor drug discovery.

Together with Exscientia’s technology, known as Centaur Chemist.

Drug is a long-acting and potent serotonin 5-HT1A receptor agonist.

New era of AI-driven drug discovery, evolving very fast.

Research by UK- Exscientia and Japan- Sumitomo Dainippon Pharma.

Mentioned in this article:

Click on resource name for more details.

Andrew Hopkins

SULSA Research Professor of Translational Biology at the School of Life Sciences, University of Dundee

Brendan Frey

Brendan Frey

Centaur Chemist

Drug Design AI, Exscientia

Deep Genomics

Canadian drug development company, AI therapeutics


Drug research and development company that specialises in automated drug discovery

Insilico Medicine

Biotechnology company that uses artificial intelligence to develop new drugs and for aging research

Paul Workman

Chief Executive and President of The Institute of Cancer Research.

Sumitomo Dainippon Pharma

R & D company based in Japan

The Institute of Cancer Research (ICR)

One of the world’s most influential cancer research organizations

Topics mentioned on this page:
AI in Healthcare, Big Pharma